Steady progress toward broader adoption of BENLYSTA treatment
Human Genome Sciences, Inc. HGSI +1.18% will today announce its priority goals for 2012 and report on progress with the commercialization of BENLYSTA(R) (belimumab), the first approved drug for systemic lupus in 56 years, during a presentation this afternoon by H. Thomas Watkins, President and Chief Executive Officer, to financial analysts and investors at the 30th Annual JPMorgan Healthcare Conference in San Francisco.
“Thousands of patients with systemic lupus are now being treated with BENLYSTA,” said Mr. Watkins. “We are pioneering a treatment in a market that has not seen a new option for patients in decades. Although we are still in the early adoption phase of our launch, our experience in the market to date reinforces our belief that BENLYSTA will ultimately play a major role in improving the standard of care for SLE patients.”
To read the full, original article click on this link: Human Genome Sciences Reports Progress with Commercialization of BENLYSTA(R) and Announces 2012 Goals at JPMorgan Healthcare Conference – MarketWatch